



## **Eiger BioPharmaceuticals to Present at the 5<sup>th</sup> Annual Liolios Gateway Conference on September 7, 2016**

**PALO ALTO, Calif., September 1, 2016** — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) has been invited to present at the [2016 Gateway Conference](#) being held on September 7-8, 2016 at the Four Seasons Hotel San Francisco.

Eiger BioPharmaceuticals management is scheduled to present on Wednesday, September 7 at 1:30 p.m. Pacific time, with one-on-one meetings held throughout the conference.

The presentation will be webcast live and available for replay in the Investor Relations section of Eiger BioPharmaceuticals website at [www.eigerbio.com](http://www.eigerbio.com) or on the Gateway Conference website at [www.gateway-conference.com/presenters](http://www.gateway-conference.com/presenters).

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [gateway@liolios.com](mailto:gateway@liolios.com).

### **About the Gateway Conference**

The 5<sup>th</sup> Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling companies with the nation's top institutional investors and analysts. This year's event features more than 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit [www.gateway-conference.com](http://www.gateway-conference.com) or [www.liolios.com](http://www.liolios.com).

### **About Eiger BioPharmaceuticals**

Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The Company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed. For additional information about Eiger and its clinical programs, please visit [www.eigerbio.com](http://www.eigerbio.com).

### **Contact:**

Jim Shaffer  
[jshaffer@eigerbio.com](mailto:jshaffer@eigerbio.com)  
(919) 345-4256